SOUTH SAN FRANCISCO, Calif., Aug. 22, 2023 /PRNewswire/ -- Neuron23™ Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced the appointment of Andrew Yost, MBA, as the company's chief business officer (CBO). Mr. Yost will be responsible for overseeing Neuron23's corporate strategy, strategic partnerships and collaborations, and licensing activities.
Earlier this year, up-and-coming biotech Neuron23 nominated its first clinical candidate, a small-molecule drug designed to inhibit the LRRK2 gene, mutations in which are commonly linked to inherited cases of Parkinson’s disease and, less commonly, non-genetic forms of the disease.
HILDEN, Germany & GERMANTOWN Md. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) and Neuron23 Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced the signing of an agreement to develop a companion diagnostic for Neuron23’s brain penetrant leucine-rich repeat kinase (LRRK2) inhibitor for Parkinson’s disease.
Neuron23™ Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological ...
Neuron23™ Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological ...